A report released earlier today by Jefferies & Co about Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) bumps down the target price to $120.00
- Updated: September 23, 2016
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) had its price target dropped to $120.00 by Jefferies & Co in an issued report announced 09/23/2016. The new stock price target indicates a possible downside of -0.06% from the company's previous closing price.
Previously on 9/22/2016, Wedbush released a statement for Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) increased the target price from $0.00 to $132.00. At the time, this indicated a possible downside of -0.01%.
Showing a price of $127.22, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded 2.55% higher on the day. The last closing price is down -1.57% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the date range. Alexion Pharmaceuticals Inc. has recorded a 50-day moving average of $131.16 and a 200-day moving average of $135.82. 1,175,594 shares of the stock traded hands, down from an avg. volume of 1,757,970
Alexion Pharmaceuticals Inc. has 52 week low of $110.56 and a 52 week high of $193.45 with a PE ratio of 335.90 and has a market capitalization of $0.
A total of 18 brokerages have issued a ratings update on the company. 7 analysts rating the company a strong buy, six brokerages rating the company a buy, seven equity analysts rating the company a hold, 0 brokers rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $187.61.
Brief Synopsis About Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.